Sugi Predict

Sugi Predict / Compounds / SCHEMBL1932302

SCHEMBL1932302

SCHEMBL1932302

Cn1cc(-c2cnc3ccc(NC(=O)Nc4ccccc4)nc3c2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 9/20 1.00
▸ MAPK1 P28482 9/20 1.00
▸ NTRK1 P04629 2/20 0.72
▸ YES1 P07947 2/20 0.72
▸ PIM1 P11309 1/20 0.72
▸ ABL1 P00519 1/20 0.72
▸ MET P08581 1/20 0.54
▸ FGFR3 P22607 3/20 0.52
▸ FGFR1 P11362 2/20 0.52
▸ FGFR2 P21802 2/20 0.52
▸ FGFR4 P22455 2/20 0.52
▸ KDR P35968 1/20 0.52
▸ EGFR P00533 1/20 0.50
▸ PIK3CA P42336 1/20 0.49
▸ MAPK8 P45983 1/20 0.49
▸ MAPK9 P45984 1/20 0.49
▸ MAPK10 P53779 1/20 0.49
▸ KIT P10721 2/20 0.49
▸ FLT3 P36888 2/20 0.49
▸ KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1933048 0.86 MAPK1 (1.00) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL1933387 0.84 MAPK1 (1.00) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL1932932 0.84 MAPK1 (1.00) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL1933036 0.82 MAPK1 (0.88) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL15726097 0.81 MAPK1 (0.70) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL14681532 0.81 AURKB (0.68) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL19441773 0.79 AURKB (0.66) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL15884468 0.79 AURKB (0.66) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL17240022 0.79 MAPK1 (0.66) AURKBMAPK1NTRK1YES1PIM1
SCHEMBL15884527 0.79 AURKB (0.64) AURKBMAPK1NTRK1YES1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2504336-B1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS ÆTERNA ZENTARIS GMBH (DE) 2016-03-30 — — EP claimed
US-8461178-B2 Naphthyridine derivatives and the use thereof as kinase inhibitors AETERNA ZENTARIS GMBH (DE) 2013-06-11 — — US claimed
EP-2504336-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS Æterna Zentaris GmbH (DE) 2012-10-03 — — EP claimed
US-20110150831-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS AETERNA ZENTARIS GMBH (DE) 2011-06-23 — — US claimed
WO-2011064250-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS ÆTERNA ZENTARIS GMBH (DE) 2011-06-03 — — WO claimed
EP-2504336-B1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS ÆTERNA ZENTARIS GMBH (DE) 2016-03-30 — — EP disclosed
EP-2504336-B1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS ÆTERNA ZENTARIS GMBH (DE) 2016-03-30 — — EP disclosed
US-8841456-B2 1,5-naphthyridine derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-09-23 — — US disclosed
US-8841456-B2 1,5-naphthyridine derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-09-23 — — US disclosed
US-20140142302-A1 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-05-22 — — US disclosed
US-20140142302-A1 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-05-22 — — US disclosed
US-8461178-B2 Naphthyridine derivatives and the use thereof as kinase inhibitors AETERNA ZENTARIS GMBH (DE) 2013-06-11 — — US disclosed
US-8461178-B2 Naphthyridine derivatives and the use thereof as kinase inhibitors AETERNA ZENTARIS GMBH (DE) 2013-06-11 — — US disclosed
US-8461178-B2 Naphthyridine derivatives and the use thereof as kinase inhibitors AETERNA ZENTARIS GMBH (DE) 2013-06-11 — — US disclosed
EP-2504336-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS Æterna Zentaris GmbH (DE) 2012-10-03 — — EP disclosed
US-20110150831-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS AETERNA ZENTARIS GMBH (DE) 2011-06-23 — — US disclosed
US-20110150831-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS AETERNA ZENTARIS GMBH (DE) 2011-06-23 — — US disclosed
US-20110150831-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS AETERNA ZENTARIS GMBH (DE) 2011-06-23 — — US disclosed
WO-2011064250-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS ÆTERNA ZENTARIS GMBH (DE) 2011-06-03 — — WO disclosed
WO-2011064250-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS ÆTERNA ZENTARIS GMBH (DE) 2011-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150831-A1 NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS MAP3K1, MAP3K20, MAP3K2 AURKB 389/4885MAPK1 26/4885NTRK1 1078/4885
US-20140142302-A1 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF NRAS, RAF1, KRAS AURKB 3666/4885MAPK1 4/4885NTRK1 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.